TBF1.F - Canntab Therapeutics Limited

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2018-05-31
2017-12-31
2017-05-31
2016-12-31
2015-12-31
Total Revenue
68
27
0
0
942
-
Cost of Revenue
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
Operating Expenses
Research Development
190
141
-
41
-
-
Selling General and Administrative
3,293
2,258
188
1,074
312
174
Total Operating Expenses
3,687
2,450
188
1,117
312
174
Operating Income or Loss
-3,619
-2,423
-188
-1,117
631
-174
Interest Expense
-
-
-
-
-
-
Total Other Income/Expenses Net
-
-
6
-
-111
0
Income Before Tax
-3,571
-2,408
-182
-1,116
520
-174
Income Tax Expense
-
-
-
-
-
-
Income from Continuing Operations
-3,571
-2,408
-182
-1,116
520
-174
Net Income
-3,571
-2,408
-182
-1,116
520
-174
Net Income available to common shareholders
-3,571
-2,408
-182
-1,116
520
-174
Reported EPS
Basic
-
-0.11
-0.40
-0.07
1.20
-0.80
Diluted
-
-0.11
-0.40
-0.07
1.00
-0.80
Weighted average shares outstanding
Basic
-
21,129
556
15,000
452
230
Diluted
-
21,129
556
15,000
520
230
EBITDA
-
-2,372
-188
-1,115
631
-174